Orchid Pharma Limited Market Cap ($490.04 Million)
Market Cap & Net Worth: Orchid Pharma Limited (ORCHPHARMA)
Orchid Pharma Limited market cap. Orchid Pharma Limited (NSE:ORCHPHARMA) has a market capitalization of $490.04 Million (Rs45.31 Billion) as of October 30, 2026. Listed on the NSE stock exchange, this India-based company holds position #12090 globally and #600 in its home market, demonstrating a 0.73% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Orchid Pharma Limited's stock price Rs893.40 by its total outstanding shares 50719105 (50.72 Million).
Orchid Pharma Limited Market Cap History (2015–2026)
Orchid Pharma Limited market cap history from 2015 to 2026. Data shows growth from $35.79 Million to $490.04 Million (27.40% CAGR). Check ORCHPHARMA live share price for real-time trading data and today's change.
Orchid Pharma Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Orchid Pharma Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Orchid Pharma Limited cash conversion from operations for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.06x
Orchid Pharma Limited's market cap is 0.06 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.38x
Orchid Pharma Limited's market cap is 2.38 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $10.26 Million | $7.97 Billion | -$4.95 Billion | 0.00x | N/A |
| 2018 | $2.63 Million | $6.83 Billion | -$3.53 Billion | 0.00x | N/A |
| 2019 | $2.99 Million | $6.00 Billion | $694.08 Million | 0.00x | 0.00x |
| 2020 | $67.60 Million | $4.84 Billion | -$1.31 Billion | 0.01x | N/A |
| 2021 | $216.61 Million | $4.50 Billion | -$1.17 Billion | 0.05x | N/A |
| 2022 | $199.68 Million | $5.60 Billion | -$19.51 Million | 0.04x | N/A |
| 2023 | $390.81 Million | $6.66 Billion | $463.18 Million | 0.06x | 0.84x |
| 2024 | $991.18 Million | $8.19 Billion | $921.66 Million | 0.12x | 1.08x |
| 2025 | $416.29 Million | $9.22 Billion | $996.57 Million | 0.05x | 0.42x |
| 2026 | $490.04 Million | $8.11 Billion | $205.47 Million | 0.06x | 2.38x |
Competitor Companies of ORCHPHARMA by Market Capitalization
Companies near Orchid Pharma Limited in the global market cap rankings as of October 30, 2026. See Orchid Pharma Limited net asset quality index to understand what proportion of total assets are financed by equity.
Key companies related to Orchid Pharma Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #600 globally with a market cap of $45.38 Billion USD ( CN¥310.15 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #626 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $45.98 |
| #600 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.38 Billion | CN¥48.62 |
| #626 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €17.90 |
Market Capitalization of Orchid Pharma Limited (2015–2026)
Market capitalization of Orchid Pharma Limited from 2015 to today. Between 2015 and today, Orchid Pharma Limited's market cap moved from $35.79 Million to $ 490.04 Million, with a yearly change of 27.40%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs490.04 Million | +17.72% |
| 2025 | Rs416.29 Million | -58.00% |
| 2024 | Rs991.18 Million | +153.62% |
| 2023 | Rs390.81 Million | +95.71% |
| 2022 | Rs199.68 Million | -7.81% |
| 2021 | Rs216.61 Million | +220.41% |
| 2020 | Rs67.60 Million | +2161.47% |
| 2019 | Rs2.99 Million | +13.54% |
| 2018 | Rs2.63 Million | -74.33% |
| 2017 | Rs10.26 Million | -30.87% |
| 2016 | Rs14.84 Million | -58.54% |
| 2015 | Rs35.79 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of Orchid Pharma Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $490.04 Million USD |
| MoneyControl | $490.04 Million USD |
| MarketWatch | $490.04 Million USD |
| marketcap.company | $490.04 Million USD |
| Reuters | $490.04 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Orchid Pharma Limited
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins; human and veterinary products; and antibiotics, including betalactam, m… Read more